Here are five insights:
1. Afinitor is the first oral therapy in the European Union’s 28 member states for this type of GI NET.
2. Afinitor’s EU approval was based on a Phase III study’s results showing Afinitor’s safety and efficacy.
3. The study’s results showed Afinitor reduced the risk of disease progression by 52 percent compared to the placebo group.
4. In February 2016, the FDA approved Afinitor to treat adult patients with progressive, well-differentiated nonfunctional NET of GI or lung origin that are surgically non-removable, locally advanced or metastatic.
5. Additional worldwide regulatory filings for Afinitor are currently underway.
More articles on GI & endoscopy:
GERD & the physician-focused 3rd generation of Stretta: Q&A with Dr. Mark Noar
SpectraScience trains Spanish physicians on optical biopsy system: 3 notes
Arsanis names gastroenterologist Dr. Anthony Stevens CMO: 4 takeaways
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.